Latest News

Our research aimed to identify whether specific aspects of health literacy (HL) are associated with quality of life (QOL) and fear of progression (FOP) in men with prostate cancer (PC). We conducted a cross-sectional study. Regarding HL, we surveyed communication skills, guideline awareness, and knowledge in several domains: PC, health care system, own physical condition, […]

Guidelines for cancer screening have been debated and are followed to varying degrees. We wanted to study whether and why doctors recommend disease-specific cancer screening to their patients. Our cross-sectional survey used a postal questionnaire. The data were examined with descriptive methods and binary logistic regression. We surveyed doctors working in all health services. Our […]

The objective of this study was to evaluate differences in tolerability in patients with metastatic castration-resistant prostate cancer treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P). This was a phase IV, prospective, open-label, multicenter, real-world study. Patients were prescribed ENZA or AA+P at the treating physician’s discretion. Computerized tests of 4 cognitive domains […]

Day 1 Session 1: Molecular biomarkers and novel imaging in APC State of the art on molecular characterization in advanced prostate cancer (Pritchard) Clinical utility of molecular markers (De Bono)  Which men need genetic counselling and/or testing? (Embargoed Until 10/14/19) (Eeles)  Advantages and pitfalls of PSMA PET/CT in APC imaging Advantages (Fanti)Pitfalls (Davis) Download Session 1 Slides […]

Basel, Switzerland (UroToday.com) Dr. van Oort discussed the important topic of managing sexuality and incontinence issues in patients with advanced prostate cancer. According to the EAU guidelines cessation of sexual activity is very common among patients treated with androgen deprivation therapy (ADT), affecting up to 93% of patients. ADT reduces both libido and the ability to […]

Randomized data assessing the longitudinal quality of life (QoL) impact of SABR in the oligometastatic setting are lacking. We enrolled patients who had a controlled primary malignancy with 1-5 metastatic lesions, with good performance status and life expectancy >6 months. We randomized in a 1:2 ratio between standard of care (SOC) treatment [SOC Arm] vs. […]

To assess the impact of primary and secondary therapies for high- and intermediate-risk prostate cancer on health-related quality of life (HRQoL). A prospective study was initiated in 2007 at Center for Prostate Disease Research Multicenter National Database sites. Longitudinal patterns in HRQoL from baseline (pre-treatment) to 5 years post-diagnosis were examined for patients with high- […]